Introduction
as attested by normalization of plasma total Hcy concentrations in 78% of patients [8] . Such efficacy Moderate elevation of plasma total homocyst(e)ine was seen, even though the concentrations of plasma (Hcy) concentration is present in the early stage of folate were lower than usually observed with folic acid chronic renal failure (CRF ), increases in parallel with treatment [8] . Moreover, no apparent toxicity was the degree of reduction in renal function, and persists noted with this regimen [8] . Although these data need after starting dialysis [1, 2] . In view of the potential confirmation by a prospective, controlled, and randomathero-thrombogenic role of hyperhomocyst(e)inaeized study, they suggest that reduced forms of folate, mia, attempts have been made to lower plasma tHcy i.e. MTHF or folinic acid, are more efficient than folic concentrations in CRF patients. Routine minimal folic acid in normalizing plasma total Hcy concentrations acid supplementation of 1 mg daily, in contrast to in CRF patients. In this editorial, we shall briefly what has been generally observed in the population at outline folate metabolism in normal subjects and CRF large, does not have an effect on plasma total Hcy patients as background information which makes it concentration, despite a supernormal plasma folate easier to understand the potential causes of such level reached in CRF patients [3] . Even worse, the increased efficacy. oral supplementation with high doses of folic acid (up to 15 mg daily), which leads to a 20-to 50-fold increase of plasma folate concentrations, is only partially effect-Folate metabolism in normal subjects ive in reducing plasma total Hcy, and only few CRF patients entirely normalize their Hcy concentrations Folates are water-soluble vitamins which are synthe- [4] [5] [6] . These data suggest the presence of resistance to sized by plants and micro-organisms. These substances folic acid action in CRF patients.
are not endogenously synthesized in the body and On the other hand, the oral treatment using the therefore are derived solely from food. Oral folates are reduced form of folate, i.e. methyltetrahydrofolate generally available in two supplemental forms, folic (MTHF ), has led to a significant decrease (70%) in and folinic acid [9, 10] . plasma total Hcy levels in 14 HD patients, with five Folic acid is a complex mixture of polyglutamate patients achieving normal total Hcy concentrations conjugate compounds with variable numbers of glu- [7] . Recently, we found that once weekly i.v. adminis-tamate molecules covalently linked to the folate moiety. tration of 50 mg folinic acid, i.e. of the immediate Folic acid is initially deconjugated in the cells of the precursor of MTHF, when associated with pyridoxine intestinal wall to monoglutamate forms by c-glutamyladministration, is even more effective in correcting the carboxypeptidase or conjugase (Figure 1) which is saturable, specific and mediated by a mem-membrane folate receptors presenting the same characteristics as serum FABP [9] . The 5-methyl group of 5-brane protein, the folic acid-binding protein (FABP) [9] . In the liver, these compounds are reduced to MTHF can only be used metabolically for transfer to Hcy via methionine synthase, which results in the dihydrofolate and subsequently to tetrahydrofolate ( THF ) via folate and dihydrofolate reductase ( Figure regeneration of methionine and THF (Figure 1) [9, 10] .
Unless THF is used for the synthesis of thymidylate 1) [9, 10] . Both enzymes require NADPH (niacin dependent) as a cofactor. The next step is the conver-or 10-formyltetrahydrofolate, it is rapidly transformed to THF polyglutamates by folylglutamyl synthetase sion of THF to 5,10-methylenetetrahydrofolate (5,10-METHF ) using serine as a major carbon source, and ( Figure 1) [9] . THF polyglutamates are used as a source of folates during periods of deprivation, since pyridoxal phosphate (B6) dependent serine hydroxymethyltransferase as an enzyme (Figure 1) . A portion they are hydrolysed to monoglutamates by folylpolyglutamyl hydrolase ( Figure 1) [9]. of 5,10-METHF thus produced undergoes irreversible enzymatic reduction to 5-MTHF by methylene tetrahyFolinic acid (5-formyl tetrahydrofolate) is an immediate precursor of 5,10-METHF. It is directly condrofolate reductase (MTHFR) (Figure 1) [9, 10] . The other portions of 5,10-METHF are required for the verted to 5,10-methenyl tetrahydrofolate by an ATP dependent enzyme, 5,10-methenyl tetrahydrofolate synthesis of thymidylate, and 10-formyltetrahydrofolate (used in purine synthesis) ( Figure 1 ) [9, 10] . After synthetase ( Figure 1) . 5,10-Methenyl, 5,10-METHF, and 10-formyl tetrahydrofolate are interconvertible [9] . 5-MTHF has been synthesized in the liver, this metabolically active compound is secreted into the small Oral administration of folinic acid bypasses the deconjugation and reduction steps required for the synthesis intestine with bile, where it is reabsorbed and distributed to tissues throughout the body ( Figure 1) [9, 10] . of folic acid, and the major proportion of folinic acid is metabolized to 5-MTHF directly during absorption The cellular uptake of 5-MTHF is in part carried out by an active transport system, probably mediated by in the intestine. Folinic acid is also available for intravenous administration. Most commercially avail-studies. Until such data are available, we think it is reasonable to wait before the routine use of reduced able folinic acid preparations are racemic mixtures of -and -isomers, but only natural -isomers are phar-forms of folate in CRF patients is proposed. Nevertheless, the above data offer new insights into macologically active [11] . Whether unnatural -isomers are inert in vivo or whether they modify specific the potential role of abnormalities of folate metabolism, particularly of MTHF, as determinants of abnoraspects of folate metabolism is still unclear [11] . mal plasma total Hcy concentrations in CRF patients.
